|Market Research A to Z | Company Profiles A to Z | Register | Contact Us | Shopping Basket|
|+44 (0) 203 086 8600 Call us on|
The global influenza products market, including vaccines, antivirals, and diagnostic products is estimated to have reached a value of around $3.8 billion by the end of 2012, and is expected to grow to $4 billion during 2013. By 2018 the industry is forecast to hit a total of $6 billion, growing at a CAGR growth rate of 8% between 2013 and 2018.
Influenza, also known as the flu, affects the upper respiratory tract and often the lungs. The infection typically lasts approximately one week, but without the use of medications the virus can continue to cause symptoms for two weeks or more. The most typical method of transmission is by moisture droplets being spread by coughing and sneezing. The young and the elderly are considered to be at a higher risk primarily due to the vulnerable state of their immune system. People with chronic diseases, such as cancer and HIV, are also at a higher risk; for them, contracting influenza can be deadly.
Annually, up to a half-million people die of influenza, and with the threat of a pandemic in any given year, government agencies and disease prevention organizations are devoted to gaining control of the situation. The 2009 pandemic generated attention to surveillance measures, pandemic preparedness, vaccine production, and antiviral control. It also revealed issues with laboratory capacity and the benefits of rapid testing in a pandemic situation.
Many companies have been asked to assist with the problem and others are furthering their position with backing from government agencies. According to BCC Research, the next five years will continue to display support and funding for many research and development programs, product development, and pandemic prevention and/or control by worldwide governments, organizations, and health professionals.
The influenza products market can be broken down into three segments, including vaccines, therapeutics, and diagnostics. All three segments are significantly impacted by seasonal factors and will be vulnerable to weak flu seasons. However, increased efforts in education for preventing influenza through vaccine use will continue to be beneficial to vaccine product developers/marketers. Several significant trends continue to influence the global influenza market including H1N1 outbreaks, Avian Flu surveillance, antiviral resistance, recreated viruses, cell-based and recombinant products, epidemic/pandemic preparedness, immaterialized market risk, and world influenza impact (seasonal and pandemic).
An aging population is a significant driver in the growth of the market, boosting sales for products directed at preventive measures, while the international market continues to show promise in vaccination, treatment, and diagnosis.
Free Research Support: Let us do the work for you and find information from public and private sources of information. Contact us now and we can save you time and money.......Free Research Support
Use our skills and global network of researchers and consultants to help find and source the business information you need.
Contact us now on 00 44 (0) 203 0868600 or "enquiries @ companiesandmarkets.com" to discuss you requirements and we can provide you with a research solution at suprisingly efficient rates and timelines.
Sometimes we can even find the information you require for free.
We are offering our clients substantial savings on the best research available during July. Please contact us either via email or by calling our team to discuss your specific research needs on Tel: 00 44 (0) 203 0868600.